With Hedera Prime, a registered CE-IVD Medical Device Software*, it only takes a few clicks from NGS results to a clinically actionable report of somatic alterations.
Consolidate biomarker testing and save time on each report with Hedera Prime
Save time with Hedera Prime Software: more somatic reports delivered daily, faster
Hedera Prime radically reduces NGS reporting turnaround time by matching genomic alterations in tumor samples with the appropriate regulatory-approved therapy options.
Pathogenicity / Oncogenicity Assessment
Pathogenicity/oncogenicity assessment through multiple databases$ including Clinvar and OncoKB™ with relevant pre-sorting
OncoKB™ Knowledge base
Hedera Prime integrates OncoKB™, precision oncology knowledge base that is updated monthly and curated by experts
Therapy options displayed in a customizable report
The report output suggests therapies options ranked by OncoKB™ Therapeutic Levels of Evidence and includes EMA and FDA approved drugs
“ESMO recommends that genomic reports include ranking of the genomic alterations for clinical actionability by valid ranking systems such as ESCAT or OncoKB™.” 1,2
Matching patient’s tumor alterations to regulatory approved therapy options with a simple solution
Certified & CE-IVD
Hedera Prime™ software is a registered CE-IVD Medical Device, enabling you to run somatic NGS tests in-house without compliance hurdles
Easy to scale
Hedera Prime software allows you to easily scale up somatic NGS tests volumes by dramatically saving time on each report
Regulatory-approved therapy options
Powered by OncoKB™, our software associates a tumor’s gene alterations with regulatory-approved therapy options and identifies effective and ineffective therapies
Seamless workflow integration
Hedera Prime software is designed to fit smoothly into your existing lab setting so you can run NGS tests quickly and efficiently
Comprehensive support
We provide service, support and resource offerings for your lab so you can run NGS tests reliably
.png)
Intuitive and robust
sample-to-report software
Streamlined
Hedera Prime is an intuitive software that has been designed to make reporting on tumor genetic variation as streamlined as possible. Developed with leading institutions and focusing on quality, Hedera Prime enables labs to provide quick and trustworthy results. By rapidly transforming raw NGS data into clinical reports, Hedera Prime allows labs to provide clinicians with the information they need more efficiently than traditional workflows.
Quickly identify that your NGS run is performing as expected
Hedera Prime helps users swiftly confirm that the run is performing as expected. Through an integrated QC dashboard, users can promptly evaluate whether essential quality control metrics for individual samples fall within expected ranges.
* A registered CE-IVD medical device for In Vitro Diagnostic Use. Not available in all countries including the United States. The computational methods to be used for the discovery and analysis of more advanced genetic variations such as gene fusions and MSI to be used for Performance Studies Only. The performance evaluation for these computational methods has not been established in this setting and users can run a local validation under CE-IVDR to use these modules as in-house IVD. Hedera Prime is manufactured by Limbus Technologies GmbH, Schillerplatz 1, 18055 Rostock, Germany. For more information please visit https://www.limbus-medtec.com/index.html
$ ClinVar, OncoKB, OMIM, gnomAD, dbSNP, Mastermind, BRCA Exchange
**EMA (European Medicines Agency) therapy options is currently also available for NSCLC samples
1. Mosele, F et al. “Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMOPrecision Medicine Working Group.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 31,11 (2020): 1491-1505.
2. Schmid, S et al. “How to read a next-generation sequencing report-what oncologists need to know.” ESMO open vol. 7,5 (2022):100570. doi:10.1016/j.esmoop.2022.100570
